Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 365

1.

Unlocking the full potential of lipid-based formulations using lipophilic salt/ionic liquid forms.

Williams HD, Ford L, Igonin A, Shan Z, Botti P, Morgen MM, Hu G, Pouton CW, Scammells PJ, Porter CJH, Benameur H.

Adv Drug Deliv Rev. 2019 May 28. pii: S0169-409X(19)30058-4. doi: 10.1016/j.addr.2019.05.008. [Epub ahead of print]

PMID:
31150666
2.

The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group.

Koziolek M, Alcaro S, Augustijns P, Basit AW, Grimm M, Hens B, Hoad CL, Jedamzik P, Madla CM, Maliepaard M, Marciani L, Maruca A, Parrott N, Pávek P, Porter CJH, Reppas C, van Riet-Nales D, Rubbens J, Statelova M, Trevaskis NL, Valentová K, Vertzoni M, Čepo DV, Corsetti M.

Eur J Pharm Sci. 2019 Jun 15;134:31-59. doi: 10.1016/j.ejps.2019.04.003. Epub 2019 Apr 8.

3.

A 30 kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats.

Kaminskas LM, Williams CC, Leong NJ, Chan LJ, Butcher NJ, Feeney OM, Porter CJH, Tyssen D, Tachedjian G, Ascher DB.

Eur J Pharm Biopharm. 2019 Apr;137:218-226. doi: 10.1016/j.ejpb.2019.03.008. Epub 2019 Mar 6.

PMID:
30851352
4.

Concentration and Recovery of Dyes from Textile Wastewater Using a Self-Standing, Support-Free Forward Osmosis Membrane.

Li M, Wang X, Porter CJ, Cheng W, Zhang X, Wang L, Elimelech M.

Environ Sci Technol. 2019 Mar 19;53(6):3078-3086. doi: 10.1021/acs.est.9b00446. Epub 2019 Mar 11.

PMID:
30801184
5.

Pointing in the Right Direction: Controlling the Orientation of Proteins on Nanoparticles Improves Targeting Efficiency.

Yong KW, Yuen D, Chen MZ, Porter CJH, Johnston APR.

Nano Lett. 2019 Mar 13;19(3):1827-1831. doi: 10.1021/acs.nanolett.8b04916. Epub 2019 Feb 21.

PMID:
30773887
6.

Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulation.

Cao E, Lindgren A, Martinsson S, Hu L, Lindfors L, Sigfridsson K, Skantze U, Michaëlsson E, Trevaskis NL, Porter CJH.

J Control Release. 2019 Feb 28;296:29-39. doi: 10.1016/j.jconrel.2019.01.002. Epub 2019 Jan 3.

PMID:
30611901
7.

A ligand-induced structural change in fatty acid-binding protein 1 is associated with potentiation of peroxisome proliferator-activated receptor α agonists.

Patil R, Mohanty B, Liu B, Chandrashekaran IR, Headey SJ, Williams ML, Clements CS, Ilyichova O, Doak BC, Genissel P, Weaver RJ, Vuillard L, Halls ML, Porter CJH, Scanlon MJ.

J Biol Chem. 2019 Mar 8;294(10):3720-3734. doi: 10.1074/jbc.RA118.006848. Epub 2018 Dec 31.

PMID:
30598509
8.

A Nonionic Polyethylene Oxide (PEO) Surfactant Model: Experimental and Molecular Dynamics Studies of Kolliphor EL.

Suys EJA, Warren DB, Pham AC, Nowell CJ, Clulow AJ, Benameur H, Porter CJH, Pouton CW, Chalmers DK.

J Pharm Sci. 2019 Jan;108(1):193-204. doi: 10.1016/j.xphs.2018.11.028. Epub 2018 Nov 28.

PMID:
30502483
9.

Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations.

Williams HD, Ford L, Han S, Tangso KJ, Lim S, Shackleford DM, Vodak DT, Benameur H, Pouton CW, Scammells PJ, Porter CJH.

Mol Pharm. 2018 Dec 3;15(12):5678-5696. doi: 10.1021/acs.molpharmaceut.8b00858. Epub 2018 Nov 13.

10.

Gel-Mediated Electrospray Assembly of Silica Supraparticles for Sustained Drug Delivery.

Ma Y, Björnmalm M, Wise AK, Cortez-Jugo C, Revalor E, Ju Y, Feeney OM, Richardson RT, Hanssen E, Shepherd RK, Porter CJH, Caruso F.

ACS Appl Mater Interfaces. 2018 Sep 19;10(37):31019-31031. doi: 10.1021/acsami.8b10415. Epub 2018 Sep 7.

PMID:
30192499
11.

Minimum information reporting in bio-nano experimental literature.

Faria M, Björnmalm M, Thurecht KJ, Kent SJ, Parton RG, Kavallaris M, Johnston APR, Gooding JJ, Corrie SR, Boyd BJ, Thordarson P, Whittaker AK, Stevens MM, Prestidge CA, Porter CJH, Parak WJ, Davis TP, Crampin EJ, Caruso F.

Nat Nanotechnol. 2018 Sep;13(9):777-785. doi: 10.1038/s41565-018-0246-4. Epub 2018 Sep 6. Review.

12.

Impact of Drug Physicochemical Properties on Lipolysis-Triggered Drug Supersaturation and Precipitation from Lipid-Based Formulations.

Alskär LC, Keemink J, Johannesson J, Porter CJH, Bergström CAS.

Mol Pharm. 2018 Oct 1;15(10):4733-4744. doi: 10.1021/acs.molpharmaceut.8b00699. Epub 2018 Sep 7.

13.

Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy.

Maganti HB, Jrade H, Cafariello C, Manias Rothberg JL, Porter CJ, Yockell-Lelièvre J, Battaion HL, Khan ST, Howard JP, Li Y, Grzybowski AT, Sabri E, Ruthenburg AJ, Dilworth FJ, Perkins TJ, Sabloff M, Ito CY, Stanford WL.

Cancer Discov. 2018 Nov;8(11):1376-1389. doi: 10.1158/2159-8290.CD-17-0841. Epub 2018 Aug 16.

PMID:
30115703
14.

Reducing Dendrimer Generation and PEG Chain Length Increases Drug Release and Promotes Anticancer Activity of PEGylated Polylysine Dendrimers Conjugated with Doxorubicin via a Cathepsin-Cleavable Peptide Linker.

Mehta D, Leong N, McLeod VM, Kelly BD, Pathak R, Owen DJ, Porter CJH, Kaminskas LM.

Mol Pharm. 2018 Oct 1;15(10):4568-4576. doi: 10.1021/acs.molpharmaceut.8b00581. Epub 2018 Sep 13.

PMID:
30107748
15.

A Path to Ultraselectivity: Support Layer Properties To Maximize Performance of Biomimetic Desalination Membranes.

Werber JR, Porter CJ, Elimelech M.

Environ Sci Technol. 2018 Sep 18;52(18):10737-10747. doi: 10.1021/acs.est.8b03426. Epub 2018 Aug 27.

PMID:
30106285
16.

Cis-regulatory determinants of MyoD function.

Soleimani VD, Nguyen D, Ramachandran P, Palidwor GA, Porter CJ, Yin H, Perkins TJ, Rudnicki MA.

Nucleic Acids Res. 2018 Aug 21;46(14):7221-7235. doi: 10.1093/nar/gky388.

17.

Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome.

Jimenez-Vargas NN, Pattison LA, Zhao P, Lieu T, Latorre R, Jensen DD, Castro J, Aurelio L, Le GT, Flynn B, Herenbrink CK, Yeatman HR, Edgington-Mitchell L, Porter CJH, Halls ML, Canals M, Veldhuis NA, Poole DP, McLean P, Hicks GA, Scheff N, Chen E, Bhattacharya A, Schmidt BL, Brierley SM, Vanner SJ, Bunnett NW.

Proc Natl Acad Sci U S A. 2018 Jul 31;115(31):E7438-E7447. doi: 10.1073/pnas.1721891115. Epub 2018 Jul 16.

18.

CD271+ Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma.

Liang L, Coudière-Morrison L, Tatari N, Stromecki M, Fresnoza A, Porter CJ, Del Bigio MR, Hawkins C, Chan JA, Ryken TC, Taylor MD, Ramaswamy V, Werbowetski-Ogilvie TE.

Cancer Res. 2018 Aug 15;78(16):4745-4759. doi: 10.1158/0008-5472.CAN-18-0027. Epub 2018 Jun 21.

PMID:
29930101
19.

Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats.

Leong NJ, Mehta D, McLeod VM, Kelly BD, Pathak R, Owen DJ, Porter CJH, Kaminskas LM.

J Pharm Sci. 2018 Sep;107(9):2509-2513. doi: 10.1016/j.xphs.2018.05.013. Epub 2018 May 29.

PMID:
29852134
20.

Mtf2-PRC2 control of canonical Wnt signaling is required for definitive erythropoiesis.

Rothberg JLM, Maganti HB, Jrade H, Porter CJ, Palidwor GA, Cafariello C, Battaion HL, Khan ST, Perkins TJ, Paulson RF, Ito CY, Stanford WL.

Cell Discov. 2018 May 1;4:21. doi: 10.1038/s41421-018-0022-5. eCollection 2018.

21.

Cyclic peptide-poly(HPMA) nanotubes as drug delivery vectors: In vitro assessment, pharmacokinetics and biodistribution.

Larnaudie SC, Sanchis J, Nguyen TH, Peltier R, Catrouillet S, Brendel JC, Porter CJH, Jolliffe KA, Perrier S.

Biomaterials. 2018 Sep;178:570-582. doi: 10.1016/j.biomaterials.2018.03.047. Epub 2018 Mar 29.

PMID:
29680158
22.

Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.

Suys EJA, Chalmers DK, Pouton CW, Porter CJH.

Mol Pharm. 2018 Jun 4;15(6):2355-2371. doi: 10.1021/acs.molpharmaceut.8b00206. Epub 2018 May 4.

PMID:
29659287
23.

Dietary docosahexaenoic acid supplementation enhances expression of fatty acid-binding protein 5 at the blood-brain barrier and brain docosahexaenoic acid levels.

Pan Y, Morris ER, Scanlon MJ, Marriott PJ, Porter CJH, Nicolazzo JA.

J Neurochem. 2018 Jul;146(2):186-197. doi: 10.1111/jnc.14342.

PMID:
29582413
24.

Lipids in the Stomach - Implications for the Evaluation of Food Effects on Oral Drug Absorption.

Koziolek M, Carrière F, Porter CJH.

Pharm Res. 2018 Feb 8;35(3):55. doi: 10.1007/s11095-017-2289-x. Review.

PMID:
29423732
25.

Fatty Acid-Binding Protein 5 Mediates the Uptake of Fatty Acids, but not Drugs, Into Human Brain Endothelial Cells.

Lee GS, Pan Y, Scanlon MJ, Porter CJH, Nicolazzo JA.

J Pharm Sci. 2018 Apr;107(4):1185-1193. doi: 10.1016/j.xphs.2017.11.024. Epub 2017 Dec 14.

PMID:
29247738
26.

Reduced blood-brain barrier expression of fatty acid-binding protein 5 is associated with increased vulnerability of APP/PS1 mice to cognitive deficits from low omega-3 fatty acid diets.

Pan Y, Choy KHC, Marriott PJ, Chai SY, Scanlon MJ, Porter CJH, Short JL, Nicolazzo JA.

J Neurochem. 2018 Jan;144(1):81-92. doi: 10.1111/jnc.14249.

27.

Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission.

Yarwood RE, Imlach WL, Lieu T, Veldhuis NA, Jensen DD, Klein Herenbrink C, Aurelio L, Cai Z, Christie MJ, Poole DP, Porter CJH, McLean P, Hicks GA, Geppetti P, Halls ML, Canals M, Bunnett NW.

Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):12309-12314. doi: 10.1073/pnas.1706656114. Epub 2017 Oct 30.

28.

Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.

McEvoy CL, Trevaskis NL, Feeney OM, Edwards GA, Perlman ME, Ambler CM, Porter CJH.

Mol Pharm. 2017 Dec 4;14(12):4525-4538. doi: 10.1021/acs.molpharmaceut.7b00660. Epub 2017 Nov 9.

PMID:
29076741
29.

Computational Models of the Intestinal Environment. 3. The Impact of Cholesterol Content and pH on Mixed Micelle Colloids.

Suys EJA, Warren DB, Porter CJH, Benameur H, Pouton CW, Chalmers DK.

Mol Pharm. 2017 Nov 6;14(11):3684-3697. doi: 10.1021/acs.molpharmaceut.7b00446. Epub 2017 Oct 5.

PMID:
28980815
30.

Ionic Liquid Forms of Weakly Acidic Drugs in Oral Lipid Formulations: Preparation, Characterization, in Vitro Digestion, and in Vivo Absorption Studies.

Sahbaz Y, Nguyen TH, Ford L, McEvoy CL, Williams HD, Scammells PJ, Porter CJH.

Mol Pharm. 2017 Nov 6;14(11):3669-3683. doi: 10.1021/acs.molpharmaceut.7b00442. Epub 2017 Oct 10.

PMID:
28954512
31.

Templated Polymer Replica Nanoparticles to Facilitate Assessment of Material-Dependent Pharmacokinetics and Biodistribution.

Song D, Cui J, Sun H, Nguyen TH, Alcantara S, De Rose R, Kent SJ, Porter CJH, Caruso F.

ACS Appl Mater Interfaces. 2017 Oct 4;9(39):33683-33694. doi: 10.1021/acsami.7b11579. Epub 2017 Sep 25.

PMID:
28945344
32.

Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site.

Ryan GM, McLeod VM, Mehta D, Kelly BD, Stanislawski PC, Owen DJ, Kaminskas LM, Porter CJH.

Nanomedicine. 2017 Nov;13(8):2485-2494. doi: 10.1016/j.nano.2017.08.003. Epub 2017 Aug 15.

PMID:
28821463
33.

An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration.

Chan LJ, Feeney OM, Leong NJ, McLeod VM, Porter CJH, Williams CC, Kaminskas LM.

Biomacromolecules. 2017 Sep 11;18(9):2866-2875. doi: 10.1021/acs.biomac.7b00794. Epub 2017 Aug 11.

PMID:
28731677
34.

Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers.

Haque S, McLeod VM, Jones S, Fung S, Whittaker M, McIntosh M, Pouton C, Owen DJ, Porter CJH, Kaminskas LM.

Eur J Pharm Biopharm. 2017 Oct;119:408-418. doi: 10.1016/j.ejpb.2017.07.005. Epub 2017 Jul 13.

PMID:
28713018
35.

Endosomal NOX2 oxidase exacerbates virus pathogenicity and is a target for antiviral therapy.

To EE, Vlahos R, Luong R, Halls ML, Reading PC, King PT, Chan C, Drummond GR, Sobey CG, Broughton BRS, Starkey MR, van der Sluis R, Lewin SR, Bozinovski S, O'Neill LAJ, Quach T, Porter CJH, Brooks DA, O'Leary JJ, Selemidis S.

Nat Commun. 2017 Jul 12;8(1):69. doi: 10.1038/s41467-017-00057-x.

36.

Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief.

Jensen DD, Lieu T, Halls ML, Veldhuis NA, Imlach WL, Mai QN, Poole DP, Quach T, Aurelio L, Conner J, Herenbrink CK, Barlow N, Simpson JS, Scanlon MJ, Graham B, McCluskey A, Robinson PJ, Escriou V, Nassini R, Materazzi S, Geppetti P, Hicks GA, Christie MJ, Porter CJH, Canals M, Bunnett NW.

Sci Transl Med. 2017 May 31;9(392). pii: eaal3447. doi: 10.1126/scitranslmed.aal3447.

37.

Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations.

Williams HD, Ford L, Lim S, Han S, Baumann J, Sullivan H, Vodak D, Igonin A, Benameur H, Pouton CW, Scammells PJ, Porter CJH.

J Pharm Sci. 2018 Jan;107(1):203-216. doi: 10.1016/j.xphs.2017.05.019. Epub 2017 May 23.

PMID:
28549907
38.

Computational Models of the Gastrointestinal Environment. 1. The Effect of Digestion on the Phase Behavior of Intestinal Fluids.

Birru WA, Warren DB, Headey SJ, Benameur H, Porter CJ, Pouton CW, Chalmers DK.

Mol Pharm. 2017 Mar 6;14(3):566-579. doi: 10.1021/acs.molpharmaceut.6b00888. Epub 2017 Feb 15.

PMID:
28099023
39.

Acute and chronic kidney disease in elderly patients with hip fracture: prevalence, risk factors and outcome with development and validation of a risk prediction model for acute kidney injury.

Porter CJ, Moppett IK, Juurlink I, Nightingale J, Moran CG, Devonald MA.

BMC Nephrol. 2017 Jan 14;18(1):20. doi: 10.1186/s12882-017-0437-5.

40.

Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods.

Crum MF, Trevaskis NL, Pouton CW, Porter CJ.

Mol Pharm. 2017 Feb 6;14(2):394-405. doi: 10.1021/acs.molpharmaceut.6b00792. Epub 2017 Jan 13.

PMID:
28002666
41.

Computational Models of the Gastrointestinal Environment. 2. Phase Behavior and Drug Solubilization Capacity of a Type I Lipid-Based Drug Formulation after Digestion.

Birru WA, Warren DB, Han S, Benameur H, Porter CJ, Pouton CW, Chalmers DK.

Mol Pharm. 2017 Mar 6;14(3):580-592. doi: 10.1021/acs.molpharmaceut.6b00887. Epub 2017 Feb 15.

PMID:
27936778
42.

Fatty Acid-Binding Protein 5 at the Blood-Brain Barrier Regulates Endogenous Brain Docosahexaenoic Acid Levels and Cognitive Function.

Pan Y, Short JL, Choy KH, Zeng AX, Marriott PJ, Owada Y, Scanlon MJ, Porter CJ, Nicolazzo JA.

J Neurosci. 2016 Nov 16;36(46):11755-11767.

43.

Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals.

Knadler MP, Nguyen TH, Campanale K, De Veer MJ, Beals JM, Li S, Hansen R, Siesky A, Michael MD, Porter CJ.

Pharm Res. 2016 Dec;33(12):2920-2929. Epub 2016 Aug 15.

44.

Glyceride-Mimetic Prodrugs Incorporating Self-Immolative Spacers Promote Lymphatic Transport, Avoid First-Pass Metabolism, and Enhance Oral Bioavailability.

Hu L, Quach T, Han S, Lim SF, Yadav P, Senyschyn D, Trevaskis NL, Simpson JS, Porter CJ.

Angew Chem Int Ed Engl. 2016 Oct 24;55(44):13700-13705. doi: 10.1002/anie.201604207. Epub 2016 Aug 2.

PMID:
27482655
45.

Lymphatic Transport and Lymphocyte Targeting of a Triglyceride Mimetic Prodrug Is Enhanced in a Large Animal Model: Studies in Greyhound Dogs.

Han S, Hu L, Gracia, Quach T, Simpson JS, Edwards GA, Trevaskis NL, Porter CJ.

Mol Pharm. 2016 Oct 3;13(10):3351-3361. Epub 2016 Sep 21.

PMID:
27608166
46.

Understanding the Challenge of Beyond-Rule-of-5 Compounds.

Bergström CAS, Porter CJH.

Adv Drug Deliv Rev. 2016 Jun 1;101:1-5. doi: 10.1016/j.addr.2016.05.016. No abstract available.

PMID:
27286746
47.

Hyaluronic Acid Molecular Weight Determines Lung Clearance and Biodistribution after Instillation.

Kuehl C, Zhang T, Kaminskas LM, Porter CJ, Davies NM, Forrest L, Berkland C.

Mol Pharm. 2016 Jun 6;13(6):1904-14. doi: 10.1021/acs.molpharmaceut.6b00069. Epub 2016 May 24.

48.

50years of oral lipid-based formulations: Provenance, progress and future perspectives.

Feeney OM, Crum MF, McEvoy CL, Trevaskis NL, Williams HD, Pouton CW, Charman WN, Bergström CAS, Porter CJH.

Adv Drug Deliv Rev. 2016 Jun 1;101:167-194. doi: 10.1016/j.addr.2016.04.007. Epub 2016 Apr 16. Review.

PMID:
27089810
49.

Passive tumour targeting and extravasation of cylindrical polymer brushes in mouse xenografts.

Müllner M, Mehta D, Nowell CJ, Porter CJ.

Chem Commun (Camb). 2016 Jul 12;52(58):9121-4. doi: 10.1039/c6cc00447d.

PMID:
27020543
50.

Improvement in Functioning and Psychological Distress in Adolescents With Postural Orthostatic Tachycardia Syndrome Following Interdisciplinary Treatment.

Bruce BK, Harrison TE, Bee SM, Luedtke CA, Porter CJ, Fischer PR, Hayes SE, Allman DA, Ale CM, Weiss KE.

Clin Pediatr (Phila). 2016 Dec;55(14):1300-1304. doi: 10.1177/0009922816638663. Epub 2016 Jul 19.

PMID:
26983448

Supplemental Content

Loading ...
Support Center